Kymera Therapeutics, Inc. 8-K

What Happened
Kymera Therapeutics, Inc. announced on March 27, 2026 (Board approved March 25, 2026) that it amended its Second Amended and Restated Bylaws to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934 (and related rules/regulations). The amendment is effective immediately and allows the Company to consent in writing to a different forum if it chooses.

Key Details

• Board approval date: March 25, 2026; amendment effective immediately.
• Scope: Exclusive forum applies to claims under the Securities Act and the Exchange Act (and their rules/regulations).
• Alternate forum: The Company may consent in writing to a different forum on a case-by-case basis.
• Filing: The full text of the bylaw amendment is filed as Exhibit 3.1 to the Form 8-K.

Why It Matters
For investors, this change standardizes where certain federal securities claims against the company must be brought, potentially reducing competing or fragmented litigation across multiple state courts. The amendment is a procedural/legal governance change in response to recent Delaware law updates; the 8-K does not state any expected financial impact.